Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. HALO
HALO logo

HALO News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

HALO News

Halozyme and Johnson & Johnson's Combination Therapy Approved

5d agoNASDAQ.COM

FDA Approves Halozyme and Johnson & Johnson's TECVAYLI for Multiple Myeloma

5d agoPRnewswire

FDA Approves Halozyme and Johnson & Johnson's TECVAYLI for Multiple Myeloma Treatment

5d agoNewsfilter

FDA Approves Johnson & Johnson's Tecvayli for Multiple Myeloma Treatment

6d agoseekingalpha

Halozyme Announces Upcoming Investor Conference Presentations

Feb 25 2026PRnewswire

Halozyme Reports Q4 2026 Earnings Miss, Stock Drops

Feb 18 2026seekingalpha

Halozyme Therapeutics Q4 2025 Earnings Call Highlights

Feb 18 2026seekingalpha

Halozyme Reports Strong Q4 and 2025 Revenue Growth

Feb 17 2026seekingalpha

HALO Events

02/17 16:10
Company Reaffirms FY26 Revenue Guidance of $1.710B to $1.810B
Reaffirms FY26 revenue $1.710B-$1.810B, consensus $1.76B. Sees FY26 Revenue from royalties $1.130B-$1.170B, representing growth of 30%-35% over 2025; adjusted EBITDA of $1.125B-$1.205B, representing growth of 71%-83% over 2025, including new Hypercon and Surf Bio investment of approximately $60M.

HALO Monitor News

Halozyme Reports Strong Revenue Growth Amid Acquisition Strategy

Feb 18 2026

Halozyme Therapeutics reaches 52-week high amid market strength

Feb 06 2026

Halozyme and Skye Collaborate on Nimacimab for Obesity Treatment

Jan 06 2026

Halozyme Therapeutics Inc Hits 20-Day Low Amid Pricing Uncertainties

Dec 03 2025

HALO.O Hits 20-Day High Amid Positive Market Sentiment

Nov 24 2025

HALO Earnings Analysis

No Data

No Data

People Also Watch